CAJ | 학술논문

目的应用IMAC预处理方案观察自体外周血干细胞移植(APBSCT) 治疗急性髓细胞自血病(AML)的疗效.方法用APBSCT治疗AML患者14例.预处理方案:IMAC.结果全部病例移植后造血重建,目前无病生存8例(57.1%),平均生存时间 26(8～72)个月,无移植相关性死亡.结论 IMAC预处理方案对AML是安全和有效的方案.预处理方案加入去甲氧柔红霉素有望提高总生存期.
목적 응용IMAC예처리방안관찰자체외주혈간세포이식(APBSCT) 치료급성수세포자혈병(AML)적료효.방법 용APBSCT치료AML환자14례.예처리방안:IMAC.결과 전부병례이식후조혈중건,목전무병생존8례(57.1%),평균생존시간 26(8～72)개월,무이식상관성사망.결론 IMAC예처리방안대AML시안전화유효적방안.예처리방안가입거갑양유홍매소유망제고총생존기.
Objective To investigate the effect of idarubiein to imensify the MAC (IMAC) as preparative regimen for autologous peripheral blood stem cell transplantation(APBSCT)in acute myeioid leukemia.Methods Fourteen patients with acute myeloid leukemia who underwent APBSCT were analysed. IMAC was used as preparative regimens.Results All patients were engrafted successfully.The disease-free survival could be Ben in 8 cases(57.1%),the median disease-free survival duration were 26(8-72)months and no treatment-related mortality was present.Conclusion This study suggested that addition of Idarubicin to the MAC preparative regimens Was safe,effective and feasible for patients with acute myeloid leukemia,and may improve disease-free survival and overall survival.